Mehra Anand
Director · Aclaris Therapeutics, Inc.
Every open-market stock purchase Mehra Anand has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where how the prices paid compare to where the stock trades now.
Where the buys stand today
- ACRSAclaris Therapeutics, Inc.
One purchase totalling $1.5M at an average of $2.25 per share. See all insider buying in ACRS →
Avg price paid$2.25Latest price—Market capUnknown
All reported buys
Follow new qualifying clusters involving Mehra Anand or other insiders
Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.
About this data
Figures are parsed from Mehra Anand's Form 4 filings on SEC EDGAR (CIK 1590102) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.
This page is informational and reflects public filing data. It is not investment advice.